Koki Nakanishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Koki Nakanishi has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Chie Tanaka
Department of Surgery, Nagoya University Hospital, Nagoya, Japan
7 shared publicationsDai Shimizu
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
6 shared publicationsMitsuro Kanda
Department of Surgery Nagoya University Hospital Showa‐ku Nagoya Japan
6 shared publicationsYasuhiro Kodera
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
6 shared publicationsMichitaka Fujiwara
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
5 shared publicationsAkiharu Ishiyama
Department of Surgery, Okazaki City Hospital, Okazaki, Japan
4 shared publications
Latest Publications
- 31 October 2026
- Published by Wiley in World Journal of Surgery
Clinical Outcomes of Surgical Treatment for Crohn's Disease‐Associated Duodenal Fistulas
- 31 October 2026
- Published by Wiley in World Journal of Surgery
Clinical Outcomes of Surgical Treatment for Crohn's Disease‐Associated Duodenal Fistulas
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Efficacy and Safety of Trifluridine/Tipiracil Plus Ramucirumab in Later-Line Treatment of Advanced Gastric Cancer: A Multicenter, Prospective Phase II Trial
PURPOSE: Trifluridine/tipiracil (FTD/TPI) plus ramucirumab may improve survival as a later-line therapy for advanced gastric cancer (GC); however, prospective evidence is limited. PATIENTS AND METHODS: We conducted a multicenter, prospective phase II trial of FTD/TPI plus ramucirumab in patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma who had received at least two previous systemic regimens for advanced disease, including a ramucirumab-containing regimen. Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received oral FTD/TPI (35 mg/m 2 , days 1-5 and 8-12) and ramucirumab (8 mg/kg, days 1 and 15) every 28 days. The primary end point was time to treatment failure (TTF), and the secondary end points were progression-free survival (PFS), overall survival (OS), response, disease control rate (DCR), relative dose intensity (RDI), and safety. RESULTS: Between February 2022 and March 2024, 32 patients were enrolled (median age, 72.5 years; 53.1% male). The median TTF was 4.0 months (95% CI, 2.8 to 5.0), meeting the primary end point. Median PFS and OS were 4.8 (95% CI, 2.8 to 8.3) and 12.2 months (95% CI, 7.8 to 17.2), respectively. Among 26 patients with measurable disease, objective response rate was 11.5%, and DCR was 76.9%. Mean RDI was 78.6% for FTD/TPI and 93.1% for ramucirumab, supporting feasibility in this cohort. Grade ≥3 neutropenia occurred in 53.1% and febrile neutropenia in 9.4%. Frequent nonhematologic events were anorexia (68.8%) and fatigue (59.4%), mostly grade 1 to 2. A modified FTD/TPI schedule was introduced in 15 patients and maintained dose delivery while reducing neutropenia, with no febrile events. CONCLUSION: FTD/TPI plus ramucirumab met its primary end point and was feasible with manageable safety in heavily pretreated advanced GC. Given the single-arm design, the efficacy findings are hypothesis-generating and warrant confirmation in larger randomized trials.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (2)
Efficacy and Safety of Trifluridine/Tipiracil Plus Ramucirumab in Later-Line Treatment of Advanced Gastric Cancer: A Multicenter, Prospective Phase II Trial
PURPOSE: Trifluridine/tipiracil (FTD/TPI) plus ramucirumab may improve survival as a later-line therapy for advanced gastric cancer (GC); however, prospective evidence is limited. PATIENTS AND METHODS: We conducted a multicenter, prospective phase II trial of FTD/TPI plus ramucirumab in patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma who had received at least two previous systemic regimens for advanced disease, including a ramucirumab-containing regimen. Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received oral FTD/TPI (35 mg/m 2 , days 1-5 and 8-12) and ramucirumab (8 mg/kg, days 1 and 15) every 28 days. The primary end point was time to treatment failure (TTF), and the secondary end points were progression-free survival (PFS), overall survival (OS), response, disease control rate (DCR), relative dose intensity (RDI), and safety. RESULTS: Between February 2022 and March 2024, 32 patients were enrolled (median age, 72.5 years; 53.1% male). The median TTF was 4.0 months (95% CI, 2.8 to 5.0), meeting the primary end point. Median PFS and OS were 4.8 (95% CI, 2.8 to 8.3) and 12.2 months (95% CI, 7.8 to 17.2), respectively. Among 26 patients with measurable disease, objective response rate was 11.5%, and DCR was 76.9%. Mean RDI was 78.6% for FTD/TPI and 93.1% for ramucirumab, supporting feasibility in this cohort. Grade ≥3 neutropenia occurred in 53.1% and febrile neutropenia in 9.4%. Frequent nonhematologic events were anorexia (68.8%) and fatigue (59.4%), mostly grade 1 to 2. A modified FTD/TPI schedule was introduced in 15 patients and maintained dose delivery while reducing neutropenia, with no febrile events. CONCLUSION: FTD/TPI plus ramucirumab met its primary end point and was feasible with manageable safety in heavily pretreated advanced GC. Given the single-arm design, the efficacy findings are hypothesis-generating and warrant confirmation in larger randomized trials.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gastric Cancer
- Vol. 26 (4) , 503
Clinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR Study
Minashi K, et al. J Gastric Cancer. 2026 ;26:e42. https://doi.org/10.5230/jgc.2026.26.e42
- 1 January 2026
- Published by XMLink in Journal of Gastric Cancer
- Vol. 26 (4) , 503
Open AccessClinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR Study
Minashi K, et al. J Gastric Cancer. 2026 ;26:e42. https://doi.org/10.5230/jgc.2026.26.e42
- Open Access
- 22 August 2024
- Published by Springer Nature in Gastric Cancer
- Vol. 27 (6) , 1331-1341
Oncological similarities between large type 3 and type 4 tumors in patients with resectable gastric cancer: a propensity score-matched analysis of a multi-institutional dataset
Background: Large type 3 (diameter ≥ 8 cm) and type 4 gastric cancers have been arbitrarily combined in Japan as a single entity. However, whether these two types are oncologically similar remain unclear. This study aimed to clarify this issue. Methods: In this retrospective study, we analyzed a database of 3,575 patients from nine institutions who underwent gastrectomy between 2010 and 2014. Using propensity scores to balance significant variables, we compared prognoses and tumor recurrences. Results: Of patients with clinical T3/T4 who underwent R0 resection, 75 and 73 had large type 3 and 4 tumors, respectively. Patients with type 4 tumors had significantly lower overall survival rates than those of patients with large type 3 tumors (hazard ratio [HR] 1.77; 95% confidence interval [CI] 1.14–2.74). However, among the large type 3 tumors, a remarkable difference in prognosis was observed between the differentiated and undifferentiated histological types. A comparison was made between large type 3 with undifferentiated phenotype and type 4, each with 39 patients after propensity score matching. Outcomes in both groups were similar in terms of overall survival (HR 1.28; 95% CI 0.73–2.25) and relapse-free survival (HR 1.34; 95% CI 0.80–2.27). No statistically significant differences were observed in the incidence of peritoneal recurrence (35.9% vs. 46.1%, P = 0.36) and lymph node recurrence (25.6% vs. 12.8%, P = 0.15). Conclusions: Large type 3 tumors with undifferentiated phenotype and type 4 tumors were oncologically similar. This subgroup could be considered as a new entity for future clinical trials.
- 22 August 2024
- Published by Springer Nature in Gastric Cancer
- Vol. 27 (6) , 1331-1341
Open AccessOncological similarities between large type 3 and type 4 tumors in patients with resectable gastric cancer: a propensity score-matched analysis of a multi-institutional dataset
Background: Large type 3 (diameter ≥ 8 cm) and type 4 gastric cancers have been arbitrarily combined in Japan as a single entity. However, whether these two types are oncologically similar remain unclear. This study aimed to clarify this issue. Methods: In this retrospective study, we analyzed a database of 3,575 patients from nine institutions who underwent gastrectomy between 2010 and 2014. Using propensity scores to balance significant variables, we compared prognoses and tumor recurrences. Results: Of patients with clinical T3/T4 who underwent R0 resection, 75 and 73 had large type 3 and 4 tumors, respectively. Patients with type 4 tumors had significantly lower overall survival rates than those of patients with large type 3 tumors (hazard ratio [HR] 1.77; 95% confidence interval [CI] 1.14–2.74). However, among the large type 3 tumors, a remarkable difference in prognosis was observed between the differentiated and undifferentiated histological types. A comparison was made between large type 3 with undifferentiated phenotype and type 4, each with 39 patients after propensity score matching. Outcomes in both groups were similar in terms of overall survival (HR 1.28; 95% CI 0.73–2.25) and relapse-free survival (HR 1.34; 95% CI 0.80–2.27). No statistically significant differences were observed in the incidence of peritoneal recurrence (35.9% vs. 46.1%, P = 0.36) and lymph node recurrence (25.6% vs. 12.8%, P = 0.15). Conclusions: Large type 3 tumors with undifferentiated phenotype and type 4 tumors were oncologically similar. This subgroup could be considered as a new entity for future clinical trials.
- 27 March 2024
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 44 (4) , 1645-1651
Risk Factors for Long-term Body Weight Loss After Proximal Gastrectomy: A Retrospective Analysis
Background/Aim: Proximal gastrectomy (PG) is a therapy for early-stage proximal gastric cancer and offers advantages such as the preservation of food storage capacity and less body weight loss (BWL). Nevertheless, significant BWL following PG may occur, affecting the patient’s well-being and survival. In this study, we aimed to identify the relevant factors for BWL following PG by analyzing an institutional database of patients. Patients and Methods: We enrolled 58 consecutive patients who underwent PG for gastric or esophagogastric junction cancer at our institution between April 2004 and March 2021. Based on BWL at 12 months postoperatively, we retrospectively compared and examined patient characteristics, surgical details, and nutritional markers. Results: The mean BWL of the 58 patients included in this analysis was 14.0±7.2%. When the patients were divided into BWL-moderate (n=29) and BWL-severe (n=29) groups using a cutoff value of 15.7%, the latter experienced early BWL within 1 month postoperatively, primarily due to body fat mass reduction, with no recovery during the 60 months of follow up. In contrast, gradual recovery was observed among patients in the BWL-moderate group after experiencing the lowest body weight 24 months postoperatively. A greater decrease in body fat mass than in muscle mass was observed in both groups. Blood hemoglobin levels did not recover in the BWL-severe group. Conclusion: The BWL-severe group after proximal gastrectomy demonstrated significantly greater early postoperative BWL, primarily attributed to a reduction in body fat mass, with hardly any recovery. Early postoperative nutritional intervention might be proposed to prevent long-term BWL.
- 27 March 2024
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 44 (4) , 1645-1651
Risk Factors for Long-term Body Weight Loss After Proximal Gastrectomy: A Retrospective Analysis
Background/Aim: Proximal gastrectomy (PG) is a therapy for early-stage proximal gastric cancer and offers advantages such as the preservation of food storage capacity and less body weight loss (BWL). Nevertheless, significant BWL following PG may occur, affecting the patient’s well-being and survival. In this study, we aimed to identify the relevant factors for BWL following PG by analyzing an institutional database of patients. Patients and Methods: We enrolled 58 consecutive patients who underwent PG for gastric or esophagogastric junction cancer at our institution between April 2004 and March 2021. Based on BWL at 12 months postoperatively, we retrospectively compared and examined patient characteristics, surgical details, and nutritional markers. Results: The mean BWL of the 58 patients included in this analysis was 14.0±7.2%. When the patients were divided into BWL-moderate (n=29) and BWL-severe (n=29) groups using a cutoff value of 15.7%, the latter experienced early BWL within 1 month postoperatively, primarily due to body fat mass reduction, with no recovery during the 60 months of follow up. In contrast, gradual recovery was observed among patients in the BWL-moderate group after experiencing the lowest body weight 24 months postoperatively. A greater decrease in body fat mass than in muscle mass was observed in both groups. Blood hemoglobin levels did not recover in the BWL-severe group. Conclusion: The BWL-severe group after proximal gastrectomy demonstrated significantly greater early postoperative BWL, primarily attributed to a reduction in body fat mass, with hardly any recovery. Early postoperative nutritional intervention might be proposed to prevent long-term BWL.
- Open Access
- 1 February 2024
- Vol. 86 (1) , 43-51
Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer
In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastric cancer. Additionally, late-line treatments, such as nivolumab, trifluridine tipiracil (FTD/TPI), or irinotecan, have limited effects on improving clinical symptoms and delaying the onset of symptoms associated with cancer progression. Recently, a combination of FTD/TPI and ramucirumab was reported to have a high response rate in late-line treatment; however, owing to patient selection bias and a high rate of hematologic toxicity in that previous study, this regimen may not be feasible in real-world clinical applications. Our objective is to conduct a single-arm phase II study to assess the safety and efficacy of FTD/TPI plus ramucirumab combination therapy for gastric cancer after third-line treatment under real-world clinical conditions. This study will recruit 32 patients according to eligibility criteria and administer FTD/TPI (35 mg/m(2)) and intravenous ramucirumab (8 mg/kg). The primary endpoint will be the time to treatment failure. The secondary endpoints will include the overall survival time, progression -free survival time, overall response rate, disease control rate, relative dose intensity, and incidence of adverse events. The results will add new insights for improving the late -line treatment of advanced gastric cancer.
- 1 February 2024
- Vol. 86 (1) , 43-51
Open AccessProtocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer
In Japan, systemic chemotherapy is the standard treatment for unresectable, advanced, or recurrent gastric cancer. However, numerous patients with gastric cancer do not receive late-line treatment because of the rapid progression of gastric cancer. Additionally, late-line treatments, such as nivolumab, trifluridine tipiracil (FTD/TPI), or irinotecan, have limited effects on improving clinical symptoms and delaying the onset of symptoms associated with cancer progression. Recently, a combination of FTD/TPI and ramucirumab was reported to have a high response rate in late-line treatment; however, owing to patient selection bias and a high rate of hematologic toxicity in that previous study, this regimen may not be feasible in real-world clinical applications. Our objective is to conduct a single-arm phase II study to assess the safety and efficacy of FTD/TPI plus ramucirumab combination therapy for gastric cancer after third-line treatment under real-world clinical conditions. This study will recruit 32 patients according to eligibility criteria and administer FTD/TPI (35 mg/m(2)) and intravenous ramucirumab (8 mg/kg). The primary endpoint will be the time to treatment failure. The secondary endpoints will include the overall survival time, progression -free survival time, overall response rate, disease control rate, relative dose intensity, and incidence of adverse events. The results will add new insights for improving the late -line treatment of advanced gastric cancer.
- Open Access
Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer
This retrospective study examined early the predictive factors for successful conversion surgery (CS) with R0 resection in patients with metastatic gastric cancer (MGC) who underwent systemic chemotherapy. This study included 204 patients diagnosed with metastatic gastric adenocarcinoma, who received chemotherapy between 2009 and 2019. Of these patients, 31 (15%) underwent CS with R0 resection. The incidence of CS with R0 resection was not affected by the volume of metastatic lesions or the presence of peritoneal metastasis. The overall survival time of the CS with R0 resection group was significantly longer than that of the non-CS group (hazard ratio, 0.12; 95% confidence interval, 0.07–0.23; p < 0.0001), with a 5 year overall survival rate of 50.2%. Multivariate analysis of 150 patients, excluding those with disease progression until the initial Response Evaluation Criteria in Solid Tumors (RECIST) evaluation, showed that carcinoembryonic antigen > 5.0 ng/mL at the initial RECIST evaluation was an independent, significant, and unfavorable predictor of CS with R0 resection (odds ratio, 0.21; p = 0.0108), whereas systemic chemotherapy with trastuzumab for HER2-positive cancer was a favorable factor (odds ratio, 4.20; p = 0.0119). Monitoring serum carcinoembryonic antigen levels during chemotherapy may be a useful predictor of the CS implementation in patients with MGC.
Open AccessLow Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer
This retrospective study examined early the predictive factors for successful conversion surgery (CS) with R0 resection in patients with metastatic gastric cancer (MGC) who underwent systemic chemotherapy. This study included 204 patients diagnosed with metastatic gastric adenocarcinoma, who received chemotherapy between 2009 and 2019. Of these patients, 31 (15%) underwent CS with R0 resection. The incidence of CS with R0 resection was not affected by the volume of metastatic lesions or the presence of peritoneal metastasis. The overall survival time of the CS with R0 resection group was significantly longer than that of the non-CS group (hazard ratio, 0.12; 95% confidence interval, 0.07–0.23; p < 0.0001), with a 5 year overall survival rate of 50.2%. Multivariate analysis of 150 patients, excluding those with disease progression until the initial Response Evaluation Criteria in Solid Tumors (RECIST) evaluation, showed that carcinoembryonic antigen > 5.0 ng/mL at the initial RECIST evaluation was an independent, significant, and unfavorable predictor of CS with R0 resection (odds ratio, 0.21; p = 0.0108), whereas systemic chemotherapy with trastuzumab for HER2-positive cancer was a favorable factor (odds ratio, 4.20; p = 0.0119). Monitoring serum carcinoembryonic antigen levels during chemotherapy may be a useful predictor of the CS implementation in patients with MGC.
- 19 August 2022
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 16 (1) , 152-156
Preoperative indocyanine green fluorescence injection to accurately determine a proximal margin during robotic distal gastrectomy
Introduction: Adequate surgical margins following gastrectomy for gastric cancer are required. In addition, a method for accurately detecting tumor location without palpation is needed during robotic surgery. Although several methods have been reported, most of these either lack accuracy or require increased time and effort during intraoperative detection. Herein, we introduce a new method for detecting tumor location using preoperative indocyanine green (ICG) marking and the built‐in ICG detection system of the da Vinci Xi Surgical System in robotic gastrectomy to determine appropriate surgical margins.Materials and Surgical Technique: We used this method to determine the resection line in six patients who underwent robotic distal gastrectomy for clinical T1 gastric cancer. One to three days before surgery, ICG was diluted to 1.0 mg/mL, and 0.1 mL of this diluted ICG solution was endoscopically injected at one site into the submucosal layer of the stomach, 1 cm proximal to the tumor edge. Gastrectomy was performed using the da Vinci Xi surgical platform, equipped with a near‐infrared fluorescence imaging system (Firefly®). The diameter of the fluorescent signal during gastrectomy was estimated to be approximately 2 cm. The resection line was determined on the outer edge of the fluorescent signal, which ensured a tumor‐free margin of ≥2 cm. Fluorescent signals were successfully observed in all cases. Moreover, the required 2‐cm surgical margin was achieved in all cases.Discussion: We could successfully determine proximal margins using preoperative ICG injection marking during robotic distal gastrectomy for gastric cancer.
- 19 August 2022
- Published by Wiley in Asian Journal of Endoscopic Surgery
- Vol. 16 (1) , 152-156
Preoperative indocyanine green fluorescence injection to accurately determine a proximal margin during robotic distal gastrectomy
Introduction: Adequate surgical margins following gastrectomy for gastric cancer are required. In addition, a method for accurately detecting tumor location without palpation is needed during robotic surgery. Although several methods have been reported, most of these either lack accuracy or require increased time and effort during intraoperative detection. Herein, we introduce a new method for detecting tumor location using preoperative indocyanine green (ICG) marking and the built‐in ICG detection system of the da Vinci Xi Surgical System in robotic gastrectomy to determine appropriate surgical margins.Materials and Surgical Technique: We used this method to determine the resection line in six patients who underwent robotic distal gastrectomy for clinical T1 gastric cancer. One to three days before surgery, ICG was diluted to 1.0 mg/mL, and 0.1 mL of this diluted ICG solution was endoscopically injected at one site into the submucosal layer of the stomach, 1 cm proximal to the tumor edge. Gastrectomy was performed using the da Vinci Xi surgical platform, equipped with a near‐infrared fluorescence imaging system (Firefly®). The diameter of the fluorescent signal during gastrectomy was estimated to be approximately 2 cm. The resection line was determined on the outer edge of the fluorescent signal, which ensured a tumor‐free margin of ≥2 cm. Fluorescent signals were successfully observed in all cases. Moreover, the required 2‐cm surgical margin was achieved in all cases.Discussion: We could successfully determine proximal margins using preoperative ICG injection marking during robotic distal gastrectomy for gastric cancer.
- 6 January 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46 (3) , 648-655
Drain Amylase Concentrations at 3 h After Gastrectomy Enhance Early Prediction of Postoperative Peripancreatic Inflammatory Fluid Collection
Background: Despite numerous studies of peripancreatic inflammatory fluid collection (PIFC) that report on the relevance of the drain amylase concentration (D‐AMY), early prediction using this assay is problematic. This study aimed to investigate the clinical significance of measuring the D‐AMY at 3 h after gastrectomy (POD0) for gastric cancer.Methods: This retrospective analysis included consecutive patients who underwent gastrectomy combined with peripancreatic lymph node dissection. The predictive value of D‐AMY on POD0 and postoperative day 1 (POD1) for clinically relevant PIFC was evaluated together or individually.Results: Analyses were performed in 204 patients. Twenty (9.8%) patients experienced PIFC. D‐AMY cutoffs of 721 IU/L on POD0 and 1695 IU/L on POD1 were determined using the receiver operating characteristic curve analysis for predicting PIFC. The D‐AMY on POD0 had higher sensitivity (80%) but lower specificity (66.3%) for prediction of PIFC, compared with those of D‐AMY on POD1 (65%, 89.1%, respectively). When combination marker analysis was performed, the highest risk group (D‐AMY ≥ the cutoff values of POD0 and POD1) were associated with an elevated rate of occurrence (44%) and a high positive likelihood ratio (7.36) compared with those of the single cutoff group. The lowest risk group (D‐AMY < the cutoff values on POD0 and POD1) was associated with a low rate of occurrence (2.5%) and low negative likelihood ratio (0.24) compared with those of the single cutoff group.Conclusions: Combined measurements of D‐AMYs on POD0 and POD1 enhanced early prediction of PIFC after gastrectomy.
- 6 January 2022
- Published by Wiley in World Journal of Surgery
- Vol. 46 (3) , 648-655
Drain Amylase Concentrations at 3 h After Gastrectomy Enhance Early Prediction of Postoperative Peripancreatic Inflammatory Fluid Collection
Background: Despite numerous studies of peripancreatic inflammatory fluid collection (PIFC) that report on the relevance of the drain amylase concentration (D‐AMY), early prediction using this assay is problematic. This study aimed to investigate the clinical significance of measuring the D‐AMY at 3 h after gastrectomy (POD0) for gastric cancer.Methods: This retrospective analysis included consecutive patients who underwent gastrectomy combined with peripancreatic lymph node dissection. The predictive value of D‐AMY on POD0 and postoperative day 1 (POD1) for clinically relevant PIFC was evaluated together or individually.Results: Analyses were performed in 204 patients. Twenty (9.8%) patients experienced PIFC. D‐AMY cutoffs of 721 IU/L on POD0 and 1695 IU/L on POD1 were determined using the receiver operating characteristic curve analysis for predicting PIFC. The D‐AMY on POD0 had higher sensitivity (80%) but lower specificity (66.3%) for prediction of PIFC, compared with those of D‐AMY on POD1 (65%, 89.1%, respectively). When combination marker analysis was performed, the highest risk group (D‐AMY ≥ the cutoff values of POD0 and POD1) were associated with an elevated rate of occurrence (44%) and a high positive likelihood ratio (7.36) compared with those of the single cutoff group. The lowest risk group (D‐AMY < the cutoff values on POD0 and POD1) was associated with a low rate of occurrence (2.5%) and low negative likelihood ratio (0.24) compared with those of the single cutoff group.Conclusions: Combined measurements of D‐AMYs on POD0 and POD1 enhanced early prediction of PIFC after gastrectomy.